30
CARDIOVASCULAR
hamburger

Stent Choice Matters

Small differences between stents can be the determining factor on whether clinical outcomes are optimal over the short and long term.1,2

There’s a Whole World of Evidence in Support of the XIENCE™ Stent

Clinicians have long had confidence in XIENCE™ Stent, which industry experts consider to be the gold standard. XIENCE™ Stent is the world's leading DES, with over 15 million implants, consistently delivering outstanding short- and long-term outcomes.1,3

Interventional cardiologists have chosen XIENCE Stent for more than 15 million implants, making XIENCE Stent the world's leading drug-eluting stent.
XIENCE Stent has been used in more than 120 clinical trials.
XIENCE Stent has been studied in over 125,000 patients in clinical trials.
XIENCE Stent has been examined in clinical trials for over a decade.

The XIENCE™ Stent difference results not just from a unique stent design but from a unique fluoropolymer coating. This coating is a key differentiator from other DES, resulting in thromboresistance, and minimal inflammatory response with XIENCE™ Stents.2,5

Peak Performance with XIENCE™ Stent

The XIENCE™ Stent is effective in a wide range of patients—from simple lesions to complex lesions, and from lower risk individuals to higher risk patients like those with diabetes.6

Here are a few of the features that contribute to XIENCE™ Stent quality and performance7

  • Excellent Deliverability
  • Ultra-low stent crossing profile (0.0390")
  • XIENCE Skypoint™ Stent's unique design to post dilate to 5.75 mm
  • Flexible and conformable MULTI-LINK design
  • Minimal stent shortening when deployed
XIENCE Sierra stent now offers best-in-class deliverability.

Ordering Options for XIENCE™ Stent

XIENCE™ Stents come in a wide range of sizes for the full spectrum of patient needs.

  • Manuals & Technical Resources
  • Cardiovascular Products
  • Customer Service

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Jinnouchi H, et al. J Am Coll Cardiol. 2019;74:Suppl B – TCT-291.
  3. Data on file at Abbott. The 15 million implants is based on DES data through Q1, 2020.
  4. Kufner S, et al. Circulation. 2019:139(3):325-333.
  5. Otsuka F, et al. JACC Cardiovasc Interv. 2015;8:1248-1260.
  6. Kaul U, et al. TUXEDO-India trial. EuroIntervention. 2017;13:1194-1201.
  7. Tests performed and data on file at Abbott. Bench test results may not necessarily be indicative of clinical performance. Testing performed on XIENCE Skypoint™ Stent (3.0 x 18 mm, n=10), SYNERGY (3.0 x 20 mm, n=10), Resolute Onyx (3.0 x 18 mm, n=10). Crossing performance - XIENCE Skypoint™ Stent (3.0 x 18 mm, n=5) and SYNERGY (3.0 x 20 mm, n=5).

MAT-2104268 v2.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.